GlaxoSmithkline Consumer Healthcare Chairman Simon Scarff to quit
GlaxoSmithkline Consumer Healthcare’s Simon Scarff will step down as chairman effective April 30, 2013. Scarff’s expressed the desire during the […]
Corporate updates
Price of cancer drugs to fall
Cancer drugs will cost almost 25% less if a new formula that calls for a price cap is implemented. The […]
Drugs to skip price control for 5 years
Drugs that boast of an element of Indian innovation can skip price control for five years under the proposed new […]
Opto Circuits’ subsidiary, Cardiac Science, rationalizes its product offering by spinning off its Diagnostic Cardiology product line
Cardiac Science, an Opto Circuits group company, signed a definitive agreement on 29th March 2013 to sell its Diagnostic Cardiology […]
Now, drug prices may be capped at time of launch
The government is considering a proposal to cap the prices of all medicines at the time of launch. This could […]
Novartis loses Indian patent case
India’s Supreme Court has rejected a plea by Novartis to patent an updated version of its cancer drug, Glivec. The […]
The changing scenario of Healthcare IT in 2013
Every New Year brings the promise of change, but even though it’s still early, when it comes to the world […]
Novartis AG to reduce stake in Novartis India
Novartis India said that its Swiss-pormoter Novartis AG plans to reduce its stake in the Indian entity to enable the […]
Docs limit patient EMR access
According to Accenture, a global consulting and technology services firm, a recent Harris Interactive survey reveals that only a third […]
Hospital launches non-invasive technology to treat fibroids
A non-invasive technology to treat uterine fibroids and adenomyosis “ Magnet Resonance guided Focussed Ultrasound Technology (MRgFUS) “ was launched […]
WHO cites TB threat
World Health Organization and Global Fund cite tuberculosis threat Urgent need for US$ 1.6 billion a year in international […]
Essential drug makers can no longer quit without informing govt
Pharma companies can no longer quit making essential drugs at will, citing non-viability, without informing the government. Drug makers will […]
Drug prices continue to remain out of control
The proposed drug pricing policy is riddled with a host of anomalies. Extending price control to all “essential” medicines will […]
-
-
Delhi to host forum on homoeopathic medicine
22-02-2017
